Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton

A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to watch–including some bracing for the next-gen entrants that arrived in 2015. One year later, those newcomers are shaking things up as expected.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS